ID Themes of 2019
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses some of the broader themes in ID over the course of 2019.
Watch
Noteworthy ID Papers of 2019
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses noteworthy infectious disease papers published in 2019.
High Rate of Errors in HIV Therapies
Daniel B. Chastain, PharmD, BCIDP, AAHIVP, discusses a retrospective study of errors occurring in the treatment of patients with HIV.
HIV Care as Patient and Provider
Jason Tokumoto, MD, discusses how occupying the role of both patient and physician can provide a human perspective on HIV care.
Developing Options For Congenital CMV
Brenna Hughes, MD, MSc, explains why we need more effective options for congenital CMV.
The Role of Guidelines in ID Treatment
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, weighs in on the role of guidelines in ID treatment.
EHR, Outreach, and Community Partners
Pamela Gorman, RN, ACRN, discusses the importance of clinics having team members who come from the community patients are being recruited from.
The Impact of Discovering U=U
Jason Tokumoto, MD, discusses recent developments in HIV treatment and prevention, focusing on the impact of “U=U.”
Expectations For Upcoming Long-Acting ART
Jason Schafer, PharmD, MPH, BCPS AQ-ID, discusses upcoming long-acting therapies for HIV.
What to Expect in December's Editor-in-Chief Letter
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, previews his editor-in-chief letter for the December issue.
Does CMV-HIG Have an Effect on Congenital Infections?
Brenna Hughes, MD, MSc, discusses the hypothesis that CMV hyperimmune globulin could have an effect on stopping congenital infections and results of a trial.
The Value of Clinic Champions
Gregory Felzien, MD, AAHIVS, highlights “clinic champions” who help move patient care forward while facing external constraints.
Long-Acting Antiretrovirals and the Cost of HIV Therapies
Carlos del Rio, MD, discusses advances in long-acting antiretrovirals and the costs associated with HIV therapies.
Peer Engagement for Navigating HIV Care
Representatives from the AIDS Care Group discuss the racial disparities that exist in the HIV/AIDS care continuum for women of color, as well as how a peer engagement and retention program can help.
What to Expect in December's News & Breakthroughs Section of Contagion®
In the December issue of Contagion®, Carlos del Rio, MD, Debra Goff, PharmD, and Paul Sax, MD, discuss the benefit of infectious disease clinicians using Twitter.
Why is it Important to Promote U=U?
Timothy Ray Brown, also known as the "Berlin Patient" discusses why it's important to push out the message that U=U.
Combining EHR and Outreach to Promote Retention in Care
Pamela Gorman, RN, ACRN, discusses how electronic health data and coordinated outreach can be combined to increase retention in care.
Polypharmacy: What Is It and How Does It Impact People Living With HIV
Jennifer Cocohoba, PharmD, summarizes her ANAC 2019 presentation on polypharmacy and how it affects people living with HIV.
Cognitive Training for People With HIV-Associated Neurocognitive Disorder
In an interview at ANAC 2019, Shameka L. Cody, PhD, AGNP-C, discusses the impact of cognitive training on quality of life outcomes for people with HIV-associated neurocognitive disorder.
Importance of Empathy in HIV Treatment
Timothy Ray Brown, formerly known as the “Berlin Patient” explains why it is important for providers to form relationships with patients and avoid stigma and judgment.
The Importance of Including Women in HIV Cure-Related Research
Brian Minalga, MSW, discusses research on the historical exclusion of women in HIV cure-related research.
Challenges of Self-Managing HIV and Diabetes
Julie Zuñiga, PhD, RN, shares findings from her research on self-management of the dual diagnosis of HIV and diabetes.
Timothy Ray Brown: HIV Cure Cheerleader
Timothy Ray Brown is the first person to ever be cured of HIV. He discusses his decision to no longer remain anonymous and why he shares his story with the world.
What is on the Horizon for HIV Prevention?
A new review in The Lancet HIV discusses the next generation of HIV prevention, called PrEP 2.0.
Read More
Traveler's Diarrhea and the Acquisition of Multidrug Resistance
Mark Riddle, MD, DrPH, speaks about his research on travelers’ diarrhea and multidrug resistance at ACG 2019.
Cefiderocol vs High-Dose Meropenem for the Treatment of Patients With Nosocomial Pneumonia
Ryan K. Shields, PharmD, MS, reacts to research presented at IDWeek 2019 on cefiderocol versus high-dose meropenem for patients with nosocomial pneumonia.
HIV Clinic Improvement and Community Engagement
Gregory Felzien, MD, discusses the surprising benefits HIV clinics encounter when they enhance community engagement.
IDWeek 2019 News Network: Assessing Challenges to Treating CABP
Thomas Lodise, PharmD, PhD, provides an overview of options for treating community-acquired bacterial pneumonia and highlights the challenges of the infection.
Community-Based HIV Care Models in Chicago
Max Brito, MD, MPH, discusses his presentation from IDWeek 2019 which compared HIV treatment in a community-based model versus a hospital-based model in Chicago.
HIV Prevention Strategies Beyond PrEP, Catalyzing Clinic Improvement
Gregory Felzien, MD, AAHIVS, discusses prevention beyond PrEP and creating a safe environment for patients with HIV.